SUPERFIBRONECTIN--A NEW ANTIMETASTATIC AGENT

描述：肿瘤的发生和转移依赖于一个复杂的系列 细胞附着被认为起着至关重要的作用 在这些过程中。申请人已经开发出一种聚合形式的 细胞黏附分子纤维连接蛋白，并已表明该制剂， 被称为超纤维连接蛋白(SFN)，也能抑制细胞附着 随着细胞在体外的迁移。在体内，SFN具有抗转移活性 对接种在免疫缺陷小鼠体内的几种人类肿瘤。 对卵巢癌细胞系的初步研究表明， 三七总皂苷能抑制注射肿瘤的生长和腹膜扩散 细胞。三氟化硫没有明显的毒性影响。 治疗。申请者建议：1)测试，作为第一步 在设计临床试验方面，三七总皂苷对慢性阻塞性肺疾病的疗效 模拟人类疾病的卵巢癌动物模型。2)评估 关注多器官组织学分析的SFN毒性 从用递增剂量的聚合物治疗的动物和3)到 开发光散射测试以标准化SFN的生产 聚合物。这些研究有望提供所需的信息。 在此第二阶段之后进行实验性临床试验 格兰特。 建议的商业应用：不可用。

DESCRIPTION: Tumorigenesis and metastasis depend upon a complex series of events, and it is believed that cell attachment plays a critical role in those processes. The applicants have developed a polymeric form of the cell adhesion molecule fibronectin and have shown that this agent, referred to as superfibronectin (sFN), inhibits cell attachment, as well as cell migration in vitro. In vivo, sFN has anti-metastatic activity towards several human tumors inoculated in immunodeficient mice. Preliminary studies with ovarian carcinoma cell lines have shown that sFN can restrict the growth and the peritoneal spread of injected tumor cells. There have been no discernible toxic effects from the sFN treatment. The applicants propose to: 1) test , as an initial step toward designing clinical trials, the therapeutic effect of sFN in an ovarian cancer animal model that mimics the human disease. 2) to assess sFN toxicity focusing on the histological analysis of multiple organs from animals treated with escalating doses of the polymer and 3) to develop a light scattering test to standardize the production of the sFN polymer. These studies are expected to provide the information needed to proceed into experimental clinical trials after the phase II of this grant. PROPOSED COMMERCIAL APPLICATION: Not available.